• Home
  • About Us
  • Contact Us
  • More
    • Home
    • About Us
    • Contact Us
  • Home
  • About Us
  • Contact Us
Vona Oncology

Mission: Providing new hope for patients with aggressive cancers

Focus

Vona Oncology is an early clinical stage bio-pharmaceutical company developing targeted therapeutics to treat aggressive cancers such as triple-negative breast cancer (TNBC), ovarian cancer and melanoma. TNBC is our initial indication for our small molecule drug, VDX-111.

Business Summary

Vona Oncology is focused on the development and commercialization of our lead compound, VDX-111. The company’s immediate objective is the completion of IND-enabling studies of VDX-111 and demonstration of early clinical phase efficacy in the treatment of TNBC. Our long-term vision is to grow Vona Oncology into a cutting-edge drug discovery and development company that can turn novel biological insights in cancer biology into actionable clinical treatments.  Vona Oncology has raised $2.65M in non-dilutive funds to date.

Product

The treatment we are developing, VDX-111, is a small molecule, well-tolerated drug that will establish a novel class of targeted therapy for treatment of TNBC.  Studies from our research team have provided proof-of-concept that VDX-111 is an efficacious therapeutic for TNBC in pre-clinical cell and animal models.  

Compelling pre-clinical data

Our studies have demonstrated strong efficacy of VDX-111 in killing TNBC cells in vitro,  and blocking TNBC tumor growth in vivo. We have identified the major target of VDX-111 in TNBC and  have shown synergy with standard of care chemotherapy. These findings open additional avenues to use and clinical benefit. 

Awards

NIH

OEDIT

OEDIT

SBIR Fast Track Grant 


"VDX-111: A Novel Targeted Therapeutic for Triple-Negative Breast Cancer"

OEDIT

OEDIT

OEDIT





Advanced Industry Accelerator Early Stage Capital Retention Grant

See press release

Copyright © 2022 Vona Oncology - All Rights Reserved.

Powered by GoDaddy